Federal Court Decisions

Decision Information

Decision Content

 

Federal Court

 

Cour fédérale


 

Date: 20101019

Dockets: T-644-09

T-933-09

 

Citation: 2010 FC 1022

Toronto, Ontario, October 19, 2010

PRESENT:     The Honourable Mr. Justice Campbell

 

 

Docket: T-644-09

BETWEEN:

APOTEX INC.

Plaintiff

 

and

 

 

SANOFI-AVENTIS

Defendant

 

 

Docket: T-933-09

AND BETWEEN:

 

 

SANOFI-AVENTIS AND

BRISTOL-MYERS SQUIBB SANOFI

PHARMACEUTICALS HOLDINGS PARTNERSHIP

Plaintiffs

 

 

and

 

APOTEX INC.

APOTEX PHARMACHEM INC. AND

SIGNA SA DE CV

Defendants

 

REASONS FOR ORDER AND ORDER

 

[1]               The issue addressed in the present Order is whether a Protonotary appeal in the present consolidated Action should be conducted as an interlocutory step leading to trial or whether it should be concluded by the Judge who will be conducting the trial. For the reasons provided, in my opinion the latter option should be put into effect.

 

[2]               On February 18, 2010, acting in her capacity as Case Management Judge in the present specially managed proceeding, Prothonotary Tabib denied Apotex’s motion to amend its pleadings (see: Apotex Inc. v. Sanofi-Aventis, 2010 FC 182). Apotex appealed Prothonotary Tabib’s decision with the matter being placed on my list for hearing on July 20, 2010. On July 16, 2010 a pre-motion teleconference was held with Counsel on the appeal in which, given that the trial in the present Action is scheduled to commence in April 2011, I expressed the opinion that, for the greatest efficiency and least disruption with respect to the trial process, by consent, the appeal should be placed before the trial judge for disposition as she or he might direct. No consent to do so was forthcoming at that time. On July 20th, the process issue was again addressed at length with the matter being adjourned to today’s date for further consideration.

 

[3]               At today’s proceeding, Counsel on the appeal confirmed that no consent exists to place the appeal in the hands of the trial judge. As a consequence, I have firmly come to the conclusion that, nevertheless, an order should be made to this effect. My detailed reasons for so finding are expressed in the transcript of the July 20th proceeding and that of today’s date, both of which form part of these reasons.

ORDER

 

Accordingly, I adjourn the appeal of Prothonotary Tabib’s decision of February 18, 2010 to the Trial Judge of the present Action for disposition as she or he might direct. 

 

“Douglas R. Campbell”

Judge

 


FEDERAL COURT

 

SOLICITORS OF RECORD

 

 

DOCKETS:                                        T-644-09 and T-933-09

 

STYLE OF CAUSE:                          APOTEX INC. v. SANOFI-AVENTIS

 

                                                            AND BETWEEN:

 

                                                            SANOFI-AVENTIS and BRISTOL-MYERS SQUIBB

SANOFI PHARMACEUTICALS HOLDINGS

PARTNERSHIP v. APOTEX INC. APOTEX

PHARMACHEM INC. AND SIGNA SA de CV

 

 

PLACE OF HEARING:                    TORONTO, ONTARIO

 

DATE OF HEARING:                      OCTOBER 19, 2010

 

REASONS FOR ORDER

AND ORDER BY:                            CAMPBELL J.

 

DATED:                                             OCTOBER 19, 2010

 

 

APPEARANCES:

 

Nando De Luca

 

 

FOR THE PLAINTIFF (Apotex Inc.)

Marc Richard

 

FOR THE DEFENDANT (Sanofi-Aventis)

 

SOLICITORS OF RECORD:

 

Goodmans LLP

Toronto, Ontario

 

FOR THE PLAINTIFF (Apotex Inc.)

Gowling Lafleur Henderson LLP

Ottawa, Ontario

FOR THE DEFENDANT (Sanofi-Aventis)

 

 

 You are being directed to the most recent version of the statute which may not be the version considered at the time of the judgment.